News
CELC
15.85
+0.51%
0.08
Weekly Report: what happened at CELC last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at CELC last week (0408-0412)?
Weekly Report · 04/15 11:31
Celcuity: A Promising Buy in Healthcare Innovation and Personalized Oncology Solutions
Gil Blum, an analyst from Needham, maintained the Buy rating on Celcuity (CELC – Research Report). The associated price target remains the same with $24.00. The company's innovative approach in cellular analysis has significant implications for cancer treatment and personalized medicine.
TipRanks · 04/12 10:07
Celcuity Inc: Statement of changes in beneficial ownership of securities
Press release · 04/10 22:06
Weekly Report: what happened at CELC last week (0401-0405)?
Weekly Report · 04/08 11:36
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
Celcuity Inc. Is a clinical-stage biotechnology company pursuing development of targeted therapies for oncology. Brian Sullivan, Chief Executive Officer, will present and be available for one-on-one investor meetings at the following investor conferences. Celcuity is seeking to raise $100 million.
Barchart · 04/04 06:05
Celcuity (NASDAQ:CELC): A Biotech with Game-Changing Blockbuster Potential
TipRanks · 04/03 04:06
Weekly Report: what happened at CELC last week (0325-0329)?
Weekly Report · 04/01 11:33
Celcuity Inc.’s Balancing Act: Navigating Financial Risks in Capital Raising Endeavors
TipRanks · 03/29 06:01
Celcuity Price Target Raised to $25.00/Share From $20.00 by Craig-Hallum
Dow Jones · 03/28 18:29
Celcuity Is Maintained at Buy by Craig-Hallum
Dow Jones · 03/28 18:29
Celcuity Up Over 20%, on Track for Highest Close Since September 2021 -- Data Talk
Celcuity Inc. (CELC) is currently at $21.88, up $3.72 or 20.48%. Company is on pace for largest percent increase since Dec. 19, 2022. Up four of the past five days. Up 111.3% from its all-time closing high.
Dow Jones · 03/28 18:26
Craig-Hallum Maintains Buy on Celcuity, Raises Price Target to $25
Benzinga · 03/28 18:19
Analysts Are Bullish on These Healthcare Stocks: Trulieve Cannabis (TCNNF), Xtant Medical Holdings (XTNT)
TipRanks · 03/28 13:10
Gedatolisib’s Promising Clinical Trial Performance and Market Potential Justify Buy Rating
TD Cowen analyst Tara Bancroft has maintained their bullish stance on Celcuity stock, giving a Buy rating today. The company's drug candidate, Gedatolisib (geda), is a candidate for treatment of advanced breast cancer. Needham also maintained their Buy rating on the stock with a $24.00 price target.
TipRanks · 03/28 12:15
Stifel Nicolaus Reaffirms Their Buy Rating on Celcuity (CELC)
TipRanks · 03/28 10:55
Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Erasca (ERAS)
TipRanks · 03/28 10:21
Celcuity Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Dow Jones · 03/28 10:18
HC Wainwright & Co. Reiterates Buy on Celcuity, Maintains $27 Price Target
Benzinga · 03/28 10:08
Celcuity Is Maintained at Buy by Needham
Dow Jones · 03/28 10:08
More
Webull provides a variety of real-time CELC stock news. You can receive the latest news about Celcuity Inc through multiple platforms. This information may help you make smarter investment decisions.
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.